Syndax Pharmaceuticals, Inc. SNDX
Set alert
As of Nov 2, 2:25 PM ET
- YTD
- -38.21%
- 1 year
- -5.23%
- Open
- 13.62
- Prev close
- 13.65
- Mkt cap
- 1.16B
- Vol
- 1.39M
- Avg vol
- 1.96M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.94
- High
- 13.75
- Forward P/E
- -16.27
- Beta
- 0.42
- Short ratio
- 8.03
- Inst. own
- 126.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 17.30
- 200-d avg
- 20.27
- 1y target
- 37.27
5D chart
Events in this range
- Nov 2, 2026Earnings: —; estimate -0.4928; surprise —%
Signals (85)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Nov 2, 10:55 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 9:35 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 9:35 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 9:35 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 4 hours ago |
| MACD: Buy Signal | Nov 2, 9:30 AM | 4 hours ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| RSI: Overbought | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 6 days ago |
News
8 hours ago defenseworld.net
Critical Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better stock? We will compare…
3 days ago globenewswire.com
Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -
3 days ago globenewswire.com
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.…
4 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are…
1 week ago zacks.com
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago globenewswire.com
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will…
1 week ago defenseworld.net
Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Monday
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Syndax Pharmaceuticals to…
1 week ago defenseworld.net
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX)
BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast…
2 weeks ago gurufocus.com
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
2 weeks ago businesswire.com
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
2 weeks ago globenewswire.com
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj®…
2 weeks ago zacks.com
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
2 weeks ago gurufocus.com
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)PR NewswireNEW YORK, Oct. 13, 2026SNDX shareholders saw the
2 weeks ago prnewswire.com
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies…
2 weeks ago benzinga.com
Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase…
2 weeks ago benzinga.com
Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
2 weeks ago benzinga.com
Crude Oil Edges Higher; Citigroup Earnings Top Views
U.S. stocks edged lower; Citi beat Q3 estimates. Bumble and BIO-key surged, while Pershing Square, Cipher Digital and Syndax fell.
2 weeks ago benzinga.com
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 200 points on Tuesday. Shares of Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) fell sharply in pre-market trading after the…
2 weeks ago benzinga.com
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.
2 weeks ago benzinga.com
Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
UnitedHealth rose after Q3 earnings and sales beat estimates; BIO-Key led gainers, while HUB Cyber Security topped premarket losers.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
2 weeks ago globenewswire.com
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – –…
3 weeks ago defenseworld.net
Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We…
1 month ago globenewswire.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October…
1 month ago seekingalpha.com
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Syndax Pharmaceuticals remains a "Strong Buy," driven by label expansion and robust revenue growth for Revuforj and Niktimvo. Company achieved FDA approval for Revuforj in r/r mNPM1 AML and is…
-
2 months ago benzinga.com
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.
-
2 months ago benzinga.com
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 33.73 percent increase over…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
-
4 months ago benzinga.com
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 Congress
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –– Ph 1 trial of revumenib with…
-
4 months ago benzinga.com
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –– Strong activity across…
-
5 months ago benzinga.com
Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of…
-
5 months ago benzinga.com
Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia
Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
-
5 months ago benzinga.com
Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –– Data underscoring…
-
5 months ago benzinga.com
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $37.
-
6 months ago benzinga.com
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $37
Barclays analyst Etzer Darout maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $35 to $37.
6 months ago benzinga.com
Earnings Scheduled For April 30, 2026
Earnings Scheduled For April 30, 2026
-
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
12 months ago benzinga.com
Earnings Scheduled For November 3, 2025
Earnings Scheduled For November 3, 2025
1 year ago benzinga.com
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket